TrialSignal
Clinical trial intelligence report
Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation in Adults Undergoing Thoracoscopic Surgery: A Randomized Controlled Trial
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT07145814
Status
COMPLETED
Phase
NA
Sponsor
People's Hospital of Guangxi Zhuang Autonomous Region
Executive brief
Investment-Ready Snapshot
This randomized controlled trial evaluated the dose-dependent effects of dexmedetomidine (DEX) on pulmonary function and aquaporin-1 (AQP1) expression during one-lung ventilation (OLV) in thoracoscopic surgery.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07145814
Indication
Acute Lung Injury(ALI)
Modality
small molecule
Target
dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline
Intervention
dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.